Janet B. McGill
Washington University in St. Louis
212 Papers
924 Citations
Janet B. McGill is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Diabetes mellitus & Medicine. The author has an hindex of 61, co-authored 182 publications.
Chat about Author
Papers
•Journal Article
Selecting among ADA/EASD tier 1 and tier 2 treatment options.
TL;DR: Each of the 4 groups of medications considered preferred therapies for treatment of T2DM by the ADA/EASD panel--insulin, sulfonylureas, TZDs, and incretin-based therapies (GLP-1 receptor agonists)--possesses significant advantages and disadvantages to be considered when individualizing treatment.
6
Cheiroarthropathy: a common disorder in patients in the t1d exchange.
Grazia Aleppo,Lauren Kanapka,Nicole C. Foster,Mengdi Wu,Mark A. Clements,Michael R. Rickels,Janet B. McGill,Roy W. Beck +7 more
TL;DR: Improved awareness of cheiroarthropathy signs and symptoms of is needed so that patients can be identified and seek treatment before the condition causes disability, particularly for adults with long-term diabetes.
6
Major decrements in glycated hemoglobin levels between 1978 and 1989 in patients with insulin-dependent diabetes mellitus.
TL;DR: It is suggested that substantial lowering of glycated hemoglobin has occurred during the last decade and this reduction should result in a lowered risk of diabetic complications.
6
Management of the 'wicked' combination of heart failure and chronic kidney disease in the patient with diabetes.
TL;DR: A review of the most recent recommendations for managing the risk of cardiorenal progression in patients with type 2 diabetes is presented in this paper , where the authors examine the use of treatments such as sodium-glucose co-transporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists, in addition to currently recommended therapies.
6
Interruption of CGM: Frequency and Adverse Consequences.
TL;DR: The RedCap survey was completed by adult patients with type 1 or type 2 diabetes (T1D or T2D) who utilize continuous glucose monitoring (CGM) followed in the Diabetes Center at Washington University in St Louis as discussed by the authors .
6